Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.
18 Years
N/A
Both
Thyroid Neoplasms
Trial Information
Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.
Resected well-differentiated thyroid neoplasms with at least one high risk feature will
receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control
rate at 2 years will be recorded.
Inclusion Criteria:
- resected well-differentiated throid cancer with at least one high risk feature for
locoregional recurrence
Exclusion Criteria:
- medullary or anaplastic thyroid cancer, unresectable
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
toxicity according to RTOG criteria
Principal Investigator
Harold Lau, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Tom Baker Cancer Centre
Authority:
Canada: Health Canada
Study ID:
18916
NCT ID:
NCT00279721
Start Date:
January 2006
Completion Date:
June 2010
Related Keywords:
- Thyroid Neoplasms
- thyroid neoplasms
- intensity modulated radiation
- radiotherapy
- Neoplasms
- Thyroid Neoplasms
- Thyroid Diseases
Name | Location |
|---|
